Skip to main content
Account
Fig. 7 | Nanoscale Research Letters

Fig. 7

From: hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway

Fig. 7

Inhibition of Wnt3a-induced β-catenin signaling by hGC33-null-NP or hGC33. a Compared with the control group, Wnt/β-catenin signaling pathway in HepG2 and Huh-7 cells treated with hGC33-null-NP or hGC33 was inhibited, and the levels of β-catenin and YAP were decreased, while the increased phosphorylated β-catenin and phosphorylated YAP molecules were unstable, and degraded in cytoplasm. The decreased β-catenin was difficult to maintain in the nucleus and drive the expression of CyclinD1, CD44, VEGF, and c-MYC, which resulted in the decrease of cyclinD1, CD44, VEGF, and c-myc protein levels. b The mechanism pattern of Wnt/β-catenin signaling pathway inhibited by hGC33-null-NP or hGC33

Back to article page

Navigation